Alvotech Seeks $125M in Public Offering and Private Placement
Event summary
- Alvotech proposes a $125M public offering of ordinary shares with a 30-day over-allotment option for underwriters.
- Concurrent private placement to professional investors in the European Economic Area.
- Proceeds to fund biosimilar development, working capital, and potential acquisitions.
- BofA Securities, Jefferies, and Evercore ISI act as joint book-running managers.
- Offering made pursuant to a previously filed and effective SEC registration statement.
The big picture
Alvotech's $125M capital raise underscores the biosimilars sector's funding needs amid competitive pressures. The move aligns with broader biotech trends of leveraging public markets for growth financing, particularly for companies with approved products and development pipelines. The strategic use of proceeds—spanning R&D, commercialization, and potential M&A—will be critical to watch as Alvotech competes with established players in the biosimilars space.
What we're watching
- Funding Allocation
- How Alvotech allocates proceeds between biosimilar development and other corporate purposes.
- Market Conditions
- Whether market conditions allow completion of the offering as proposed.
- Strategic Moves
- The pace at which Alvotech pursues acquisitions or collaborations with the new capital.
Related topics